<DOC>
	<DOCNO>NCT01519856</DOCNO>
	<brief_summary>Non-Ergot Dopamine agonist meanwhile drug first-choice treatment Parkinson 's disease . The receptor profile non-ergot dopamine-agonist piribedil unique . In addition agonistic effect dopaminergic D2- D3-receptors piribedil adrenergic alpha-2A- alpha-2C-receptors antagonisic property . There evidence literature antagonistic property piribedil correlate improvement cognitive function vigilance parameter parkinson 's disease . The aim present non-interventional study investigate safety efficacy piribedil long-term therapy patient M. Parkinson consideration cognitive function quality life .</brief_summary>
	<brief_title>PIRLONG-PD Safety Efficacy Piribedil Parkinson 's Disease During Long Term Therapy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Piribedil</mesh_term>
	<criteria>newly diagnose advanced idiopathic Parkinson 's disease male female patient 18 year age indication treatment piribedil accord Summary Product Characteristics ( SmPC ) line piribedil SmPC particular hypersensitivity piribedil excipients pregnancy lactation state SmPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>open</keyword>
	<keyword>non-intervention</keyword>
	<keyword>observational</keyword>
</DOC>